Intra-Cellular Therapies, Inc. provided earnings guidance for the full year 2023. For the year, the company expected CAPLYTA net product sales guidance increased to $445 to $465 million from the previous range of $430 to $455 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.93 USD | -0.70% | +3.52% | -5.15% |
16/05 | Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM | |
07/05 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.15% | 7.17B | |
-0.28% | 90.59B | |
-0.92% | 38.99B | |
-9.57% | 34.09B | |
+64.83% | 26.38B | |
-17.98% | 15.02B | |
-6.74% | 13.17B | |
-9.76% | 11.88B | |
-47.31% | 10.65B | |
+7.34% | 9.25B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023